Torsades De Pointes
Torsades De Pointes - Related Videos
12:15
Quantification of three DNA Lesions by Mass Spectrometry and Assessment of Their Levels in Tissues of Mice Exposed to Ambient Fine Particulate Matter
0 Views •
Cited by 1 •
2019
We describe here methods for sensitive and accurate quantification of the lesions 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodGuo), 1,N6-etheno-2'-deoxyadenosine (1,N6-dAdo) and 1,N2-etheno-2'-deoxyguanosine (1,N2-dGuo) in DNA. The methods were applied to the assessment of the effects of ambient fine particulate matter (PM2.5) in tissues (lung, liver and kidney) of exposed A/J mice.
09:07
Live-Cell Imaging of Transcriptional Activity at DNA Double-Strand Breaks
0 Views •
Cited by 2 •
2021
This protocol presents a new reporter gene system and the experimental setup to detect transcription at DNA double-strand breaks with single-molecule sensitivity.
07:12
Using Informational Connectivity to Measure the Synchronous Emergence of fMRI Multi-voxel Information Across Time
0 Views •
Cited by 23 •
2014
Informational connectivity measures the correspondence between time courses of multi-voxel information across different brain regions. Multi-voxel pattern discriminability time series are extracted from regions and compared, revealing networks that are not identified in a typical functional connectivity approach.
14:25
Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans
0 Views •
2019
This work describes a robust and straightforward method to detect and quantify the endocannabinoid 2-arachidonoylglycerol (2-AG) in C. elegans. An analytical deuterated standard us prepared and used for the quantification of 2-AG by isotopic dilution and liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS).
04:45
Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome
0 Views •
Cited by 4 •
2022
The present protocol describes a lung injury model in mice using oleic acid to mimic acute respiratory distress syndrome (ARDS). This model increases the inflammatory mediators on edema and decreases lung compliance. Oleic acid is used in the salt form (oleate) since this physiological form avoids the risk of embolism.
FAQs
Delayed ventricular repolarization prolongs the QT interval and extends the period during which ventricular cells may develop early afterdepolarizations, electrical disturbances that occur before repolarization is complete. These afterdepolarizations can reach threshold and generate a premature ventricular beat. In a susceptible myocardium, that beat can initiate the twisting polymorphic rhythm, making it the immediate trigger.
These conditions are important modifiers of susceptibility rather than interchangeable diagnoses. Hypokalemia and hypomagnesemia are recognized risk factors, while bradycardia can also favor the setting in which delayed repolarization becomes dangerous. When they accompany a QT-prolonging medication, the combined profile warrants closer attention to electrocardiographic findings and possible drug interactions.
Drug interactions matter because the total pharmacologic risk may reflect more than one medication. A QT-prolonging antiarrhythmic or another QT-prolonging drug can become more concerning when combined with interacting therapies or with hypokalemia, hypomagnesemia, or bradycardia. Reviewing the complete medication profile therefore helps identify preventable combinations before an arrhythmia develops.
When evaluating a QT-prolonging medication, assess the drug class, the patient's concurrent therapies, and the presence of hypokalemia, hypomagnesemia, or bradycardia. Certain antiarrhythmics and other medications require particular attention because they can prolong QT. Pairing this review with electrocardiographic monitoring supports a more complete assessment of potential adverse effects.
Electrocardiographic monitoring provides a way to follow the QT interval during pharmacologic treatment and recognize delayed ventricular repolarization as a safety signal. It is especially relevant when clinicians assess QT-prolonging drugs, potential interactions, or adverse effects. The resulting information can support safer prescribing and earlier attention to a pattern associated with sudden cardiac death.
The arrhythmia links a measurable electrocardiographic concern, QT prolongation, with a potentially life-threatening outcome. That connection makes it relevant when evaluating antiarrhythmics and other medications, assessing adverse effects, and considering drug interactions. Pharmacology therefore uses this risk context to support safer prescribing, appropriate monitoring, and efforts to prevent sudden cardiac death.